Shorter regimens for treatment of latent tuberculosis in the Northern Territory: apragmatic effectiveness study

TB Unit, Northern Territory Centre for Disease Control0 个研究点目标入组 240 人开始时间: 2019年12月4日最近更新: 2022年10月10日

适应症

试验速览

暂无简介。

•Patients with latent tuberculosis infection diagnosed by positive tuberculin skin test (TST) or Interferon-Gamma Release Assay (IGRA), in whom active TB disease has been excluded, and there is a clinical indication for treatment of latent tuberculosis infection.

•Children less than two years of age or body weight less than 10kg
•Anyone with presumed or confired TB disease or is undergoing treatment for TB disease
•Those with presumed infection with isoniazid or rifampicin resistant Mycobacterium tuberculosis
•Pregnant women or women who expect to become pregnant during the twelve week course of treatment
•Those taking any medication which may result in a clinically significant interaction with isoniazid or rifapentine, including people with HIV infection taking antiretroviral medications which may interact with rifapentine such as protease inhibitors or nevirapine.
•Those with a history of allergic reaction or hypersensitivity to isoniazid, rifapentine or rifamycins
•Those with a AST level that is three or more times higher than the upper limit of normal
•Anyone under consideration for solid organ transplantation
•Anyone with a history of porphyria

发起方

TB Unit, Northern Territory Centre for Disease Control